Erythropoietin (Epo) governs mammalian erythropoiesis. Epo is a glycoprotein hormone mainly produced in the kidney and liver in response to changes in tissue oxygen tension. Epo regulates erythropoiesis by supporting the survival of erythroid progenitors and stimulating their differentiation and proliferation in bone marrow, hence increasing the oxygen-carrying capacity of blood
[1]. Lack of Epo during mouse development leads to lethality at embryonic day 13.5 (E13.5) due to severe anemia
[2] and over- or under-production of Epo results in polycythemia or anemia clinically
[1]. Epo production is considered to be controlled primarily at the level of gene transcription and
Epo gene expression is strictly regulated in a tissue/cell-specific and hypoxia/anemia-induced manner
[3]–
[7].
Several tissues have been reported to express the
Epo gene; but the ability to produce substantial amounts of Epo during hypoxia/anemia is restricted to the fetal liver and adult kidney
[4]–
[8]. The kidney plays a major role in oxygen sensing and contributes ~90% of plasma Epo in adult animals
[9]. However, difficulties in identification and purification of the renal Epo-producing cells (REPs) have limited the understanding of the mechanism for controlling Epo production in kidney. REPs are frequently reported to be peritubular fibroblast-like cells in kidney
[6],
[10],
[11]; and a hypoxia-dependent Epo-producing cell line derived from human renal cancer was also described recently to exhibit fibroblast-like phenotype
[12]. However, further details remain to be elucidated
[5],
[7],
[13].
Current knowledge of the molecular mechanisms of oxygen-sensing and renal
Epo gene expression has been extrapolated mostly from in vitro studies in hepatoma cell lines
[14]–
[16]. These studies have suggested that hypoxia responsiveness of the
Epo gene depends on an enhancer containing hypoxia-responsive elements (HREs) located in the 3′ flanking region of the gene (3′ enhancer), to which the hypoxia-inducible transcription factor (HIF) 1 binds. HIF1 is composed of two subunits, HIF1α and HIF1β. HIF1β is constitutively expressed, but HIF1α expression, almost absent in normoxia, is increased during hypoxia. Under normoxic conditions, HIF1α is hydroxylated at two proline residues by specific prolyl-4-hydroxylases (PHD1–3) that allow the E3 ubiquitin ligase von Hippel-Lindau (pVHL) to bind to HIF1α and mark it for proteasomal degradation. In addition, HIF1α is regulated by the aspargine hydroxylase factor inhibiting HIF1 (FIH1), which inhibits p300/CBP (CREB-Binding Protein) binding to HIF1α. The activities of PHD and FIH1 are basically dependent on cellular oxygen concentration and thus qualify as cellular oxygen sensors. Low oxygen tension causes inactivation of PHDs and FIH1, allows HIFα to accumulate, forms active transcription factor-complex HIF with HIF1β, recruits transcriptional cofactors, and initiates the transcription of hypoxia responsive genes including the
Epo gene. Thus the PHD/pVHL/HIF system likes to be the oxygen-sensing pathway regulating
Epo gene transcription
[17].
However, recent clinical and
in vivo studies have suggested a new layer of complexity to the mechanisms involved in the cellular response to hypoxia/anemia. Evidence from mouse models and hereditary erythrocytosis in humans has revealed that HIF2α rather than HIF1α plays a vital role in oxygen-regulated erythropoiesis and renal Epo production is probably regulated by PHD2/pVHL/HIF2α pathway
[13],
[18],
[19]. There are three HIFα family members: HIF1α, HIF2α, and HIF3α, which share a number of similarities
e.g. DNA-binding sequence, oxygen-dependent hydroxylation. Unlike ubiquitously expressed HIF1α, expression of HIF2α and HIF3α is limited to several tissues
[20]. Both HIF1α and HIF2α activate transcription, while HIF3α negatively regulates HIF1α and HIF2α activity
[20]–
[22]. There is no literature on HIF3α's role in hematopoiesis thus far.
In order to clarify the whole picture of
Epo gene regulation, we have generated a panel of mouse lines. First, we genetically deleted the 3′ enhancer (referred to as the
EpoΔ3′E allele) and showed that this enhancer is necessary for hepatic
Epo expression during the perinatal period {E17–postnatal day 13 (P13)} but dispensable for renal
Epo expression after birth. Mice homozygous for the targeted allele (
EpoΔ3′E/Δ3′E) are viable and fertile, but exhibit anemia during late-embryonic and newborn stages
[23]. Then, using a 180-kb
Epo transgene with a green fluorescent protein (GFP) reporter (
Epo-GFP), we recapitulated tissue-specific, hypoxia-inducible GFP expression in kidney and liver tissue of mouse. Mutation studies on the transgene indicated that GATA factors are required for suppression of ectopic expression of the gene, but not essential for the
Epo gene induction in REPs
[6]. Also, we developed GFP knock-in mice (
EpoGFP/wt) by homologous recombination in mouse embryonic stem cells (NS and MY, unpublished data). By examining these mouse lines, we identified GFP-labeled REPs as a population of peritubular interstitial cells in the kidney after birth.
Taken together, all these data in vivo strongly imply novel mechanism(s) and necessitate detailed studies on REPs to explore a specific oxygen-sensing pathway underlying the hypoxia-induced Epo production in the kidney.
Fluorescence activated cell sorting (FACS) of GFP expressing cells has been widely used for the isolation of hematopoietic stem cells in our laboratory
[24],
[25]. To make the link between the molecular and cellular mechanisms of hypoxia-induced
Epo expression, in this paper, we have addressed controversial issues in REPs using cell-sorting techniques. Our
Epo-GFP transgenic mice are a source of REPs isolation, but a pretreatment to induce anemia is not always successful for stable GFP expression in the kidney
[6]. We therefore generated
EpoGFP/Δ3′E mice, in which REPs were labeled with GFP as a result of neonatal anemia caused by genetic modifications. Taking advantage of the strong GFP expression in anemic newborns carrying the 3′ enhancer deletion, we have purified by FACS a cell population responsible for anemia/hypoxia induced
Epo expression in the kidney.